Survival Benefit of Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer: A Multi-institutional Case Control Study

Background Hyperthermic intraperitoneal chemotherapy (HIPEC) and complete surgical removal of the tumor, in relapsing patients may provide a clinical benefit. There is no consensus considering the place of HIPEC for patients who had first ovarian cancer relapse. To assess for possible efficacy of HI...

Full description

Saved in:
Bibliographic Details
Published in:Annals of surgical oncology 2014-10, Vol.21 (11), p.3621-3627
Main Authors: Le Brun, Jean-François, Campion, Loic, Berton-Rigaud, Dominique, Lorimier, Gérard, Marchal, Frédéric, Ferron, Gwenael, Oger, Anne Sophie, Dravet, François, Jaffre, Isabelle, Classe, Jean-Marc
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Case-Control Studies
Chemotherapy, Cancer, Regional Perfusion
Combined Modality Therapy
Female
Follow-Up Studies
Gynecologic Oncology
Humans
Hyperthermia, Induced
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Recurrence, Local - mortality
Neoplasm Recurrence, Local - pathology
Neoplasm Recurrence, Local - therapy
Neoplasm Staging
Oncology
Ovarian cancer
Ovarian Neoplasms - mortality
Ovarian Neoplasms - pathology
Ovarian Neoplasms - therapy
Prognosis
Retrospective Studies
Surgery
Surgical Oncology
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Hyperthermic intraperitoneal chemotherapy (HIPEC) and complete surgical removal of the tumor, in relapsing patients may provide a clinical benefit. There is no consensus considering the place of HIPEC for patients who had first ovarian cancer relapse. To assess for possible efficacy of HIPEC on overall survival (OS) rates in this situation, we performed a multi-institutional study. Methods The current study was a retrospective case control multi-institutional study comparing a group of patients treated with HIPEC to a group of patients treated without HIPEC. Inclusion criteria were first relapse of a serous ovarian carcinoma and >6 months after the end of initial treatment. Exclusion criteria were another pathological subtype of ovarian cancer, a relapse at 
ISSN:1068-9265
1534-4681
DOI:10.1245/s10434-014-3693-7